Aprepitant for CLIFAHDD Syndrome

This trial tests aprepitant, a drug typically used to treat nausea and vomiting in chemotherapy patients, to determine its safety for individuals with CLIFAHDD syndrome. CLIFAHDD is a serious genetic disorder affecting nerves and muscles, leading to developmental delays and muscle weakness. Researchers aim to discover if aprepitant can enhance daily life for those with this condition. Individuals with a confirmed CLIFAHDD diagnosis who can travel to San Antonio, Texas for study visits may be suitable candidates for this trial. As an Early Phase 1 trial, this research focuses on understanding how aprepitant works in people with CLIFAHDD syndrome, offering participants a chance to contribute to groundbreaking research.

You may need to stop taking certain medications to join the trial, especially if they interact with the study drug. If you're taking specific drugs like pimozide or certain antibiotics, you might need to discuss with the study team to see if you can safely stop them.

Research has shown that aprepitant has been safely used by many people. Testing has involved about 6,800 individuals, and studies indicate it is generally well-tolerated. Only a small number of people experience mild side effects, such as a hot flush or skin rash, which are rare and may affect up to 1 in 100 people. The FDA has already approved aprepitant for treating nausea and vomiting in children and adults undergoing chemotherapy, establishing its safety record. Overall, no serious side effects have been linked to its use as an anti-nausea treatment.¹²³⁴⁵

Most treatments for CLIFAHDD syndrome focus on managing symptoms rather than targeting the underlying mechanisms of the condition. Aprepitant is unique because it is an NK1 receptor antagonist, which offers a new approach by potentially addressing the neurological pathways involved in the syndrome. Researchers are excited about aprepitant because of its potential to improve symptoms more effectively than current options, which mainly include symptomatic relief with medications that do not target the underlying causes. This novel mechanism of action could lead to better outcomes for patients with CLIFAHDD syndrome.

Research has shown that aprepitant, a drug typically used to prevent nausea and vomiting from chemotherapy, blocks certain signals in the brain. This mechanism might alleviate symptoms of CLIFAHDD syndrome. Aprepitant has proven safe and effective for other conditions, such as chronic itching and chemotherapy-induced nausea. Although specific studies on aprepitant for CLIFAHDD are lacking, its mechanism suggests potential benefits. This trial will assess the safety and tolerability of aprepitant in participants with CLIFAHDD, aiming to improve their quality of life by targeting similar pathways.⁶⁷⁸⁹¹⁰